Bei Akademie registrieren
BEL 20, BE0389555039

BEL 20 Gains 0.60% to New Record at Brussels Close

Published on 11/05/2026 at 18:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The BEL 20 rose 0.60 percent at the Brussels close on Thursday, reaching another record high. UCB led the advance, while Melexis, Aperam and Sofina weighed on the index.

BEL 20 reaches another record

  • The BEL 20 gained 0.60 percent at the Brussels close on Thursday, November 5.
  • Healthcare, telecommunications and consumer-services stocks supported the index, while Melexis, Aperam and Sofina lagged.
  • UCB was the strongest BEL 20 constituent, rising 2.69 percent to a record close.
BEL 20, BE0389555039, Illustration mit AI erstellt.
BEL 20, BE0389555039, Illustration mit AI erstellt.

The BEL 20 extended its record run on Thursday, November 5, closing 0.60 percent higher in Brussels. The advance followed the previous session's 2.42 percent rise, when the index closed at 5,979.01 points, according to Euronext.

Healthcare stocks lead the advance

A Reuters-sourced report published by Investing.com said gains in healthcare, telecommunications and consumer services supported the market. UCB rose 2.69 percent, or 7.60 points, to 290.20 euros and reached a record closing level. Elia gained 2.38 percent to 133.60 euros, while Syensqo advanced 1.87 percent to 79.00 euros.

Index breadth remained mixed

Despite the higher index close, the session was not uniformly positive. UCB was the strongest performer among the reported constituents, while Melexis fell 4.89 percent to 52.50 euros. Aperam declined 2.28 percent to 34.32 euros and Sofina lost 2.08 percent to 273.00 euros. Advancing shares outnumbered decliners by 45 to 42, with 12 stocks unchanged on the Brussels exchange.

Record territory raises the benchmark

The move above 6,000 points during Thursday's trading had already marked a new milestone for the Belgian benchmark. VRT reported that the index had broken above that level after closing at 5,979 points on Wednesday, with the advance supported in particular by AB InBev, argenx, KBC and UCB. The latest close keeps the BEL 20 in record territory, although the mixed individual-stock performance shows that the rise was not driven equally across all constituents.

For investors, the next session will be assessed against Thursday's record close and the continued performance of heavyweight healthcare, financial and consumer companies. Further information is available on the BEL 20 topic page.

Disclaimer...
en | BE0389555039 | BEL 20 | boerse | 70465830 |